Manning & Napier Advisors LLC Boosts Holdings in Sanofi $SNY

Manning & Napier Advisors LLC raised its stake in shares of Sanofi (NASDAQ:SNY) by 18.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 196,003 shares of the company’s stock after buying an additional 31,003 shares during the quarter. Manning & Napier Advisors LLC’s holdings in Sanofi were worth $9,251,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the stock. Exencial Wealth Advisors LLC increased its holdings in Sanofi by 4.9% in the 3rd quarter. Exencial Wealth Advisors LLC now owns 66,553 shares of the company’s stock valued at $3,141,000 after acquiring an additional 3,107 shares during the last quarter. Concurrent Investment Advisors LLC grew its position in shares of Sanofi by 3.3% during the third quarter. Concurrent Investment Advisors LLC now owns 12,634 shares of the company’s stock valued at $596,000 after purchasing an additional 408 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in shares of Sanofi by 8.6% in the third quarter. TD Private Client Wealth LLC now owns 120,147 shares of the company’s stock worth $5,671,000 after purchasing an additional 9,506 shares during the last quarter. First Horizon Corp purchased a new stake in shares of Sanofi in the third quarter worth about $33,000. Finally, MGO One Seven LLC boosted its stake in Sanofi by 15.7% during the third quarter. MGO One Seven LLC now owns 29,215 shares of the company’s stock valued at $1,379,000 after buying an additional 3,956 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Trading Down 0.8%

Shares of Sanofi stock opened at $47.20 on Wednesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.30. The stock’s 50 day simple moving average is $49.12 and its 200-day simple moving average is $48.87. The stock has a market cap of $115.12 billion, a P/E ratio of 11.05, a P/E/G ratio of 1.19 and a beta of 0.45. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 24th. The company reported $2.91 earnings per share for the quarter, beating the consensus estimate of $1.60 by $1.31. The business had revenue of $15.46 billion during the quarter, compared to analysts’ expectations of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The business’s revenue for the quarter was down 7.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.25 EPS. Analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Cowen reaffirmed a “hold” rating on shares of Sanofi in a research note on Tuesday, December 30th. HSBC restated a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. Barclays downgraded shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research report on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.67.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.